mRNA vs Pox-Vectored Vaccines Against Mpox, Cost-Effectiveness of Prophylactic Use of the Anti-RSV Monoclonal for Infants, and How Molnupiravir Leads to Better Outcomes 3 and 6 Months After Treatment
Login to view comments.
Click here to Login
